November 10, 2017
WAILEA, Hawaii — Perioperative administration of Rh-Endostatin with traditional chemotherapy improved outcomes for patients with stage IIB osteosarcoma, according to study results presented at Connective Tissue Oncology Society.
“[The regimen] could significantly improve the distant metastasis-free survival and overall survival of [these patients],” Xiaohui Niu, MD, of the department of orthopedic oncology at Beijing Ji Shui Tan Hospital in China, said during a presentation. “This is a preliminary and exciting result. It is the first drug that could improve OS in the past 30 years. A randomized multicenter clinical trial is needed.”